All In Biotech

Drug Trial Radar · NCT04689100

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

A Phase I, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor.

Last checked: Nov 19, 2026Latest source record: Dec 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

259

Planned (sponsor's estimate)

Start

Apr 11, 2017

Primary completion

Dec 31, 2021

Study completion Jun 30, 2022

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
Collaborators
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
First posted
Dec 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.

Conditions

  • Advanced Solid Tumor

Interventions

  • JMT101Drug

    Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)

  • JMT101Drug

    IV infusion Q2W (28-day cycles)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (defined by the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE V4.03)).Time frame: From enrollment until 30 days after the last dose
  2. Number of Subjects Experiencing DLTs (Dose Limiting Toxicity).Time frame: Time from the first dose of study drug up to 4 weeks
  3. Maximum Tolerated Dose (MTD)Time frame: 28 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Luhe Hospital. Capital Medical University

    Beijing, China · Recruiting

  • Peking University Cancer Hospital

    Beijing, China · Recruiting

  • The first affiliated hospital of bengbu medical college

    Bengbu, China · Recruiting

  • The First People's Hospital of Changzhou

    Changzhou, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • The Sixth Affiliated Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • Zhongshan Hospital

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.